Pancreatology xxx (2015) 1–6

Contents lists available at ScienceDirect

Pancreatology

journal homepage: www.elsevier.com/locate/pan

Original article

New-onset type 2 diabetes mellitus – A high-risk group suitable for the screening of pancreatic cancer?

Dóra Illés, Viktória Terzin, Gábor Holzinger, Klára Kosár, Richárd Róka, Gábor Zsóri, György Ábrahám, László Czakó*

First Department of Medicine, University of Szeged, Szeged, Hungary

ARTICLE INFO

Article history:
Available online xxx

Keywords:
Diabetes mellitus
Pancreatic cancer
Screening
Ca 19-9
Abdominal ultrasonography
Standardized incidence ratio

ABSTRACT

Background: Type 2 diabetes mellitus is widely considered to be associated with pancreatic cancer.
Objective: To determine the incidence of pancreatic cancer in new-onset type 2 diabetic patients by measuring the serum level of CA 19-9 and performing abdominal ultrasonography (US).
Patients and methods: Consecutive type 2 diabetic patients in whom diabetes was diagnosed within 36 months were included in this prospective study. Serum CA 19-9 measurement and US were performed in all patients. If any of two was positive, abdominal computer tomography (CT) was carried out. Endoscopic ultrasound-guided fine needle aspiration or direct surgical referral was performed on patients with CT-identified lesions.
Results: A total of 115 patients were enrolled. CA 19-9 was elevated in 10 patients but pancreatic cancer diagnosed in neither of them. Pancreatic cancer was revealed by morphological means in three patients without elevated CA 19-9 level. The sensitivity, specificity, positive-, negative predictive values and validity were 0%, 90.4%, 0%, 97.9% and 87.9% for CA 19-9, 66.7%, 100%, 100%, 99% and 99% for US, respectively. The value of the Standardized Incidence Ratio for pancreatic cancer in new-onset type-2 diabetic patients was 198.6 (95% CI = 6.25–46.9).
Conclusions: The prevalence of pancreatic cancer in patients with new-onset type-2 diabetes is significantly higher than that in the general population and screening is beneficial for detecting PaC in this patient population. CA 19-9 and US is not reliable screening modality for pancreatic cancer screening in this population.

Introduction

The reported annual incidence of pancreatic cancer (PaC) lies in the range 1–10 cases/100.000 persons worldwide [1], and is 5.4 cases/100.000 persons in Hungary [2]. Although the disease accounts for only 3% of all cancer cases [3], it has a very high mortality rate: it is the fourth and the fifth leading cause of cancer-related death in the USA [4] and in Europe [5], respectively. Surgery is the only possibility as curative treatment, but unfortunately only 15% of the patients are eligible for curative resection at the time of the diagnosis because of the presence of metastases and locoregional infiltration [6]. An efficient screening programme for the early diagnosis of PaC in the asymptomatic stage is needed to improve the prognosis. Population-wide screening is not feasible and not cost-effective, because the lifetime prevalence of PaC is only 1.39% [7]. It is recommended that subjects at high risk of PaC should be screened.

The prevalence of type 2 diabetes mellitus (T2DM) in PaC patients has been reported to be 40%, and 50% of T2DM patients with PaC have T2DM with a duration of 2 years or less [8]. Patients with short-term T2DM (<4 years) have more than 1.5-fold risk of displaying PaC as compared with patients who have DM with a duration of ≥5 years [9]. Pannala et al. reported that patients diagnosed with T2DM have an 8-fold higher risk of PaC developing within 2–3 years after the diagnosis of T2DM relative to the general population [10]. The fasting blood glucose level is known to be elevated in 85% of PaC cases [11], which suggests that new-onset T2DM is a paraneoplastic sign of PaC, caused by the malignancy

* Corresponding author. First Department of Medicine, University of Szeged, Szeged, P.O. Box: 427, H-6701, Hungary. Tel.: +36 62 545187; fax: +36 62 545185.
E-mail address: czako.laszlo@med.u-szeged.hu (L. Czakó).

http://dx.doi.org/10.1016/j.pan.2015.12.005

itself. Individuals with new-onset T2DM might serve as an appropriate group to be screened for PaC.

Attention has turned to tumourmarkers as possible screening modalities, because they are cheap, easy to perform and widely available. The carbohydrate antigen 19-9 (CA 19-9) is the most reliable tumourmarker for PaC. CA 19-9 is a tumour-associated, but not tumour-specific epitope of sialyated Lewis A blood group antigen [12], which occurs in the epithelium of the salivary glands and in the ductal cells of the biliary tracts and is secreted by the exocrine pancreas too [13]. The sensitivity of this marker for PaC is 70–90%, the specificity is 90%, the positive predictive value is 69% and the negative predictive value is 90% [14–19]. However, even a test with a sensitivity and a specificity of 95% would yield numerous false-positive findings besides each true-positive result and it is therefore recommended to combine CA 19-9 measurement with an imaging tool for more efficient screening [20].

Imaging modalities are the gold standard for the diagnosis of PaC. A weekness of these examinations is that they are not able to detect PaC measuring <1 cm, when the tumour is frequently resectable. The most effective imaging techniques for the detection of PaC are multidetector computer tomography (CT) and endoscopic ultrasonography (EUS) [21]. The sensitivity of transabdominal ultrasonography (US) in the diagnosis of PaC is only 50–70% [22]. However, US is easy to use, widely available, non-invasive and relatively inexpensive, making it an ideal screening modality.

We set out to determine the incidence of PaC prospectively in new-onset T2DM patients by measuring the serum level of CA 19-9 and performing US.

Patients and methods

Patients

Between March 2012 and October 2014, 115 consecutive patients with new-onset T2DM were enrolled by diabetologists of our clinic into this prospective study. The diagnosis of T2DM was made in accordance with the criteria of the American Diabetes Association (ADA) [23]. New-onset DM is defined as DM diagnosed first within the last 36 months before the time of enrolment [11]. Cases with T1DM and any kind of symptoms indicative of pancreatic disease were excluded. The duration of follow-up was 36 months from the first visit. All patients provided their written informed consent to participation. The study protocol was in full accordance with the most recent revisions of the Helsinki Declaration and was approved by the ethics committee at the University of Szeged (approval No. 97/2012).

Methods

The serum CA 19-9 level was measured and transabdominal US was performed at the first visit. In accordance with local laboratory standards, the cut-off serum CA 19-9 level was 27 U/mL. If the transabdominal US indicated any abnormality (with either a normal or an elevated CA 19-9 level), abdominal CT was performed. EUS, EUS-guided fine-needle aspiration (EUS-FNA) and surgical referral were carried out if the CT revealed a pancreatic lesion.

In the event of an elevated serum CA 19-9 level without any US abnormality, abdominal CT was performed. When the CT did not show any lesion the serum CA 19-9 level was repeated in 3 months' time. When the CA 19-9 level was normal and the US was negative, the CA 19-9 level was measured 6-monthly and US was performed yearly (Fig. 1).

Potential risk factors for PaC, i.e. an age >65 years [24], hereditary syndromes predisposing to PaC and any first-degree relatives with PaC besides DM, were documented at the first visit and were each scored with one point. The body mass index (BMI; abnormally high if $\geq$ 25 kg/m^2) [25] and the smoking status were also registered.

Person-time incidence rate has been calculated, because we compared two populations where exposures are changing within subjects over time [26].

To assess the eligibility of the patients with new-onset T2DM as a risk group for PaC, the standardized incidence ratio (SIR) was calculated with the person time incidence based on our study and the age-adjusted incidence of PaC in Hungary (9.3 cases/100.000 persons) [1]. The SIR is used to determine whether the occurrence of cancer in a comparatively small, specific group is higher or lower than that in the normal population [27]. A SIR of 1 indicates that the number of cancer cases observed in the population evaluated is equal to the number of cancer cases expected in the general population. An SIR > 1 indicates that more cancer cases occurred than expected [28].

To examine the efficacy of CA 19-9 and US as potential diagnostic tools for PaC, the sensitivity, specificity and positive and negative predictive values were calculated.

Results

A total of 115 patients with new-onset T2DM were enrolled into the study (49 male, 66 female, mean age: 58 ± 11 y, range: 32–85 y). 7 patients were subsequently excluded for various reasons: 1 man had T1DM, 1 woman had polycystic ovarium syndrome and 5 patients later declined to participate. The average time between the diagnosis of T2DM and inclusion in the study was 3.5 ± 4.4 months (range 0–20 months).

Out of three patients (2.78%), each had one first-degree relative with PaC, one patient had PaC. Sixty-nine (64%) of the participants scored 1 point, 38 (35%) scored 2 points and 1 patient (1%) scored 3 points on our risk-estimating system (Table 1). Patients had no specific symptoms suspicious for PaC.

The serum CA 19-9 level was elevated in 10 patients (9%) (52.613 ± 23.13 U/mL), but none of them exhibited morphological abnormalities on either US or CT.

The imaging examinations revealed a mass in the pancreas in 3 patients (2.78%) without an elevated serum CA 19-9 level. The mean age of the patients with PaC was 70 ± 7 years and their average BMI was 30.1 ± 5.1 kg/m^2 vs. 58 ± 11 years and 30.5 ± 4.6 kg/m^2, respectively in the patients with T2DM only. The time between CA 19-9 test/US examination and CT examinations was 1 ± 1.7 months. These 3 cases are discussed below.

Case 1

A 67-year-old non-smoking woman was diagnosed with T2DM 8 months before the first study visit. She had a positive history for various tumours (kidney, parotid and thyroid gland) and had a first-degree relative with PaC. Her BMI was 25.4 kg/m^2. She scored 3 points (new-onset DM, age, positive family history for PaC) on our risk-estimating system. The CA 19-9 level was normal. US demonstrated a 30 mm hypoechogenic solid lesion, which was confirmed by CT. EUS-FNA revealed pancreatic ductal adenocarcinoma. The patient was inoperable due to the presence of multiple metastases in the right lung. Chemotherapy induced regression and the patient was still alive at the writing of the manuscript (Fig. 2).

Case 2

A 65-year-old man was diagnosed with T2DM 3 months before inclusion. His BMI was 29.4 kg/m^2. He has not smoked for 7 years.

Please cite this article in press as: Illés D, et al., New-onset type 2 diabetes mellitus – A high-risk group suitable for the screening of pancreatic cancer?, Pancreatology (2015), http://dx.doi.org/10.1016/j.pan.2015.12.005